Market Overview

RBC Says Biogen Can Move 10% After BIIB-037 Data Is Revealed

Related BIIB
Get Ready For A Slew of Data As Weekend Nears
18 Biggest Mid-Day Losers For Thursday
Biotech ETFs Defy Trump Tweets To Rally, But What Can Send Them Higher? (Investor's Business Daily)

Biogen Inc (NASDAQ: BIIB) is down 3 percent on Friday after commentary from Cowen. Analyst Eric Schmidt suggested investors not play the company's upcoming AAIC data reveal centered on Aducanumab, scheduled for July 22, due to a lack of conviction.

It didn't take long for RBC's trading desk to respond.

In a note circulating among traders, the firm said it believes "the primary reason for the action is due to a competitor report that relates to a bit more cautious/balanced tone on upcoming Alzheimer's data," though Cowen was not specifically mentioned.

Related Link: Douglas Williams To Leave Biogen For Biotechnology Start-Up

RBC admitted new placebo data could change the overall outlook for Biogen's drug, but added it's not a new idea. "In addition, the company hasn't presented in public in almost two months so there haven't been any comments by the company," the firm added.


It's thought the market is expecting a 40 to 50 percent chance of success for Aducanumab. Schmidt's note said he sees a 60 to 70 percent range if AAIC data impresses investors, and a 20 percent mark if it whiffs. He said these numbers in turn give Biogen stock a possibility of swinging $50 in either direction.

RBC puts the probability of Aducanumab success at 65 percent, but warns, "we won't know that for a while as Phase III is just starting." In its eyes, Biogen could move $38 to $39 in either direction after the data release -- a 10 percent swing.

Latest Ratings for BIIB

Mar 2017Morgan StanleyDowngradesOverweightEqual-Weight
Mar 2017Leerink SwannDowngradesOutperformMarket Perform
Feb 2017CitigroupUpgradesNeutralBuy

View More Analyst Ratings for BIIB
View the Latest Analyst Ratings

Posted-In: AducanumabAnalyst Color Biotech Previews Analyst Ratings Movers Trading Ideas General


Related Articles (BIIB)

View Comments and Join the Discussion!